trial summary · NCT07437963
Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse
Phase 1/2 Study of Dinutuximab/Cyclophosphamide/Topotecan/Sargramostim (GM-CSF) With or Without Iberdomide in Children With Relapsed, Refractory, or Progressive Neuroblastoma Following Prior Chemoimmunotherapy
Trial record from the TrialBase DB dataset, status RECRUITING, condition Recurrent Ganglioneuroblastoma, sponsored by National Cancer Institute (NCI). Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
This phase I/II trial studies the side effects and best dose of iberdomide when given together with chemoimmunotherapy drugs and to see how well it works in treating patients with neuroblastoma that has come back after a period of improvement (relapsed), that does not respond to treatment (refractory), or that is growing, spreading, or getting worse (progressive) following prior chemoimmunotherapy. Iberdomide is a cereblon-modulating agent. It works by helping the immune system kill tumor cells. Chemoimmunotherapy is chemotherapy combined with immunotherapy. Chemotherapy drugs, such as cyclophosphamide and topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with dinutuximab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Granulocyte-macrophage colony-stimulating factors (GM-CSF), such as sargramostim, may increase the production of blood cells and may help the immune system recover from the side effects of chemotherapy. Giving iberdomide with chemoimmunotherapy may be safe, tolerable, and/or effective in treating patients with relapsed, refractory, or progressive neuroblastoma following prior chemoimmunotherapy.
Source record: https://clinicaltrials.gov/study/NCT07437963
Facts
| registry id | NCT07437963 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE1/PHASE2 |
| study type | INTERVENTIONAL |
| lead condition | Recurrent Ganglioneuroblastoma |
| sponsor | National Cancer Institute (NCI) |
| sponsor class | NIH |
| enrollment | 76 |
| start date | 2027-06-25 |
| primary completion | 2029-09-30 |
| completion | 2029-09-30 |
| results posted | not reported |
Conditions
- Recurrent Ganglioneuroblastoma
- Recurrent Neuroblastoma
- Refractory Ganglioneuroblastoma
- Refractory Neuroblastoma
Interventions
- Bone Marrow Aspiration
- Bone Marrow Biopsy
- Computed Tomography
- Cyclophosphamide
- Dinutuximab
- Echocardiography Test
- FDG-Positron Emission Tomography
- Iberdomide
- Magnetic Resonance Imaging
- Multigated Acquisition Scan
- Nuclear Radiology Imaging Procedure
- Sargramostim
1 more in the dataset.
Countries
- United States
Intervention types: BIOLOGICAL, DRUG, PROCEDURE, RADIATION
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.